Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 11 - 15 save search
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
Published: 2021-11-15 (Crawled : 19:00) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ARWR | $22.52 -4.86% -5.11% 1.1M
|
Health Technology
|
| O: -3.29%
H: 0.86%
C: -10.19%
phase 2 hepatitis phase 2b injection infections chronic hepatitis b
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
Published: 2021-11-15 (Crawled : 18:00) - metacrine.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 1.6%
H: 2.36%
C: -0.79%
diabetes phase 2 results topline nash trial phase 2b
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
Published: 2021-11-15 (Crawled : 17:00) - biospace.com/
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 1.63%
H: 0.43%
C: -0.3%
phase 2
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
RDHL | $0.3935 2.21% 2.16% 240K
|
Health Technology
|
| O: -2.83%
H: 0.0%
C: 0.0%
covid phase 2 biopharma ongoing phase 2/3
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
Published: 2021-11-15 (Crawled : 14:00) - ir.anaptysbio.com
ANAB | $21.47 0.61% 0.61% 300K
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
phase 1 positive topline phase 2 phase 3
Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery
Published: 2021-11-15 (Crawled : 14:00) - biospace.com/
MRNA | News S | $103.45 -0.33% -0.33% 2M
|
Health Technology
|
| O: 2.19%
H: 0.0%
C: 0.0%
phase 2 positive
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
RCKT M | $23.7 -2.27% -2.32% 640K
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: -23.94%
disease phase 1 positive trial phase 2 phase 3 rp-a501 danon disease
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
NVCR | $12.04 -3.37% -3.49% 1.4M
|
Health Technology
|
| O: 3.0%
H: 0.39%
C: -3.17%
phase 2 positive results trial topline glioblastoma
Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis
Published: 2021-11-15 (Crawled : 12:00) - prnewswire.com
PTGX | $25.55 -2.15% -2.19% 520K
|
Health Technology
|
| O: 4.69%
H: 0.0%
C: 0.0%
phase 2 potential positive therapy phase 2b
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
Published: 2021-11-15 (Crawled : 09:00) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ADXN | $22.8 0.89% 0.88% 16K
|
Health Technology
|
| O: 2.85%
H: 1.14%
C: 1.14%
phase 1 phase 2 xin phase 3
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.